Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

Appointment of Non-Executive Director

YORK, 17 July, 2013 - Tissue Regenix Group plc ("Tissue Regenix" or "the Group") (AIM:TRX), the regenerative medical devices company, today announces the appointment of Steven Couldwell as a non-executive director of the Group. His appointment follows that of Randeep Singh Grewal to non-executive director on 10 July 2013.

Steven's appointment will provide invaluable support to the Group's management team with his experience of building successful international businesses based on pioneering technology.

Steven has a proven international track record in driving revenues and profit growth in both the medical device and CRO industries. With over 14 years of senior management experience, Steven is currently Vice President and Head of Global Biosurgery at Sanofi, which has revenues of approximately $750m.

Steven was also formerly Vice President and General Manager of Covance Laboratories Europe and worked for Smith & Nephew for almost 20 years in a number of roles including President Orthopaedics (Europe) and Senior VP Sales and Marketing for Smith & Nephew's Advanced Wound Management business.

This appointment represents a further progression in the composition of the Board, increasing its diversity and experience with independent non-executive directors with substantial healthcare industry experience, to complement the executive management team and help guide the commercialisation of Tissue Regenix's products. Steven joins at a crucial stage in the Group's international development, following the establishment of its USA subsidiary 'Tissue Regenix Wound Care Inc.' in November 2012, and the recent signing of the USA processing partnership with Community Tissue Services in June 2013.

John Samuel, Executive Chairman of Tissue Regenix, said: "We are confident that Steven's proven international experience in the medical device sector will make a major contribution to the future of the Group. His particular expertise in the orthopaedic and wound care sectors will prove extremely beneficial and complements Randeep Singh Grewal's investment expertise. Steven and Randeep's appointments will be invaluable as the Group progresses towards full commercialisation of our product range over the coming months and years."

In accordance with Schedule 2(g) of the AIM Rules, the following information in relation to the appointment of Steven Couldwell is disclosed:

Mr Steven Ashley Couldwell, aged 53, holds or has held directorships/partnerships in the five years preceding his appointment at the Group as follows:

Current Directorships / Partnerships:

None

Previous Directorships / Partnerships:

Covance Laboratories Limited 

Smith & Nephew Orthopaedics Limited

There is no further information which is required to be disclosed in respect of Steven Couldwell pursuant to Schedule 2 (g) of the AIM Rules.

-ENDS-

For Further Information

Tissue Regenix Group plc: +44 (0) 19 0443 5176

Antony Odell

John Samuel

Jefferies International Ltd. +44 (0) 20 7029 8000

Simon Hardy

Harry Nicholas

Newgate Communications +44 (0) 207 680 6550

Alistair Kellie

Andrew Jones

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.